In respiratory, we will continue to increase our share both through the development of new products and through selling into new and developing geographical markets. We will maintain our competitive position by continuing to leverage Continuous Improvement (CI) activities as products move into the mature stage of their product life cycle.
Our strategy for the auto-injector sector is focused on the commercialisation of the existing pipeline in conjunction with the development of further IP and the exploitation of "Innovation on Demand" opportunities through our growing Innovation team based in Cambridge. We will continue to move up the value chain by offering assembly and drug handling and will continue to look for additional, selective acquisitions.
Our strategy for the nasal market is focused on the delivery of our existing development programmes plus further exploitation of our growing IP portfolio via a number of "Innovation on Demand" opportunities.
Our approach to the Nicotine Delivery sector is to successfully industrialise & commercialise the Nicoventures device, and then to increase the value add content, and exploit wider geographic opportunities as the business and market develops.
The POC Diagnostic strategy is focused on the commercialisation of the Atlas device as a first stage penetration of the market. Following a successful outcome to this programme we will leverage our development, manufacturing and regulatory know-how in order to grow our market share, possibly in conjunction with selective acquisitions.
In conclusion, Bespak's strategy is to continue to grow by exploiting its current and emerging competencies, in both existing and adjacent market sectors, in a mixed model of proprietary IP protected products and contract manufacturing, whilst harnessing more of the value chain to include drug handling and final QP release to the market.